Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma? (Q89599313)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32033478 AND SRC:MED&resulttype=core&format=json

6 April 2020

review article

4 references

28 January 2021

30 January 2021

9 October 2022

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32033478 AND SRC:MED&resulttype=core&format=json

serine/threonine-protein kinase TOR

6 April 2020

main subject

1 reference

phosphoinositide-3 kinase inhibitor

28 January 2021

1 reference

small lymphocytic lymphoma

30 January 2021

1 reference

9 October 2022

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32033478 AND SRC:MED&resulttype=core&format=json

6 April 2020

author name string

Chiara Tarantelli

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32033478 AND SRC:MED&resulttype=core&format=json

6 April 2020

Antonio Lupia

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32033478 AND SRC:MED&resulttype=core&format=json

6 April 2020

Anastasios Stathis

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32033478 AND SRC:MED&resulttype=core&format=json

6 April 2020

publication date

5 February 2020

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32033478 AND SRC:MED&resulttype=core&format=json

6 April 2020

28 January 2021

30 January 2021

9 October 2022

International Journal of Molecular Sciences

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32033478 AND SRC:MED&resulttype=core&format=json

6 April 2020

28 January 2021

30 January 2021

9 October 2022

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32033478 AND SRC:MED&resulttype=core&format=json

6 April 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32033478 AND SRC:MED&resulttype=core&format=json

Creative Commons Attribution

6 April 2020

copyright license

3 references

28 January 2021

30 January 2021

9 October 2022

0 references

Specificity in recognition of phosphopeptides by src-homology 2 domains.

1 reference

12 December 2020

A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system

1 reference

12 December 2020

NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling

1 reference

12 December 2020

Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes

1 reference

12 December 2020

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

12 December 2020

Upstream and downstream of mTOR

1 reference

12 December 2020

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

1 reference

12 December 2020

Cancer-specific mutations in PIK3CA are oncogenic in vivo

1 reference

12 December 2020

Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase

1 reference

12 December 2020

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

12 December 2020

Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia

1 reference

12 December 2020

Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival

1 reference

12 December 2020

The GLUT4 glucose transporter

1 reference

12 December 2020

mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer

1 reference

12 December 2020

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

1 reference

12 December 2020

PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma

1 reference

12 December 2020

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity

1 reference

12 December 2020

Mutations of the PIK3CA gene in diffuse large B cell lymphoma

1 reference

12 December 2020

Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85alpha subunit of phosphoinositide-3 kinase

1 reference

12 December 2020

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

12 December 2020

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

1 reference

12 December 2020

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

1 reference

12 December 2020

Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia

1 reference

12 December 2020

Targeting the phosphoinositide 3-kinase pathway in cancer

1 reference

12 December 2020

Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma

1 reference

12 December 2020

The PI3K pathway as drug target in human cancer

1 reference

12 December 2020

Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor

1 reference

12 December 2020

The emerging mechanisms of isoform-specific PI3K signalling

1 reference

12 December 2020

The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma

1 reference

12 December 2020

Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha

1 reference

12 December 2020

PTENtumor suppressor plays less prognostic role thanP53tumor suppressor in diffuse large B-cell lymphoma

1 reference

12 December 2020

Pushing the envelope in the mTOR pathway: the second generation of inhibitors

1 reference

12 December 2020

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

1 reference

12 December 2020

Hallmarks of Cancer: The Next Generation

1 reference

12 December 2020

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway

1 reference

12 December 2020

Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?

1 reference

12 December 2020

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

1 reference

12 December 2020

The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells

1 reference

12 December 2020

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

1 reference

12 December 2020

PI3Kδ Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic

1 reference

12 December 2020

Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia

1 reference

12 December 2020

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

1 reference

12 December 2020

NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.

1 reference

12 December 2020

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

1 reference

12 December 2020

The chemical biology of phosphoinositide 3-kinases

1 reference

12 December 2020

Inhibitors of B-cell receptor signaling for patients with B-cell malignancies

1 reference

12 December 2020

Low expression level of phosphatase and tensin homolog deleted on chromosome ten predicts poor prognosis in chronic lymphocytic leukemia

1 reference

12 December 2020

Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.

1 reference

12 December 2020

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

1 reference

12 December 2020

The genetic landscape of mutations in Burkitt lymphoma

1 reference

12 December 2020

Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.

1 reference

12 December 2020

Genetic heterogeneity of diffuse large B-cell lymphoma

1 reference

12 December 2020

PAK1 mediates resistance to PI3K inhibition in lymphomas.

1 reference

12 December 2020

P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse

1 reference

12 December 2020

An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo

1 reference

12 December 2020

Memory of conditioned taste aversion is erased by inhibition of PI3K in the insular cortex

1 reference

12 December 2020

Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.

1 reference

12 December 2020

Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism

1 reference

12 December 2020

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma

1 reference

12 December 2020

Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency

1 reference

12 December 2020

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia

1 reference

12 December 2020

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

1 reference

12 December 2020

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells

1 reference

12 December 2020

Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.

1 reference

12 December 2020

The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains

1 reference

12 December 2020

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

1 reference

12 December 2020

Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway

1 reference

12 December 2020

Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma

1 reference

12 December 2020

PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo

1 reference

12 December 2020

Constitutive AKT activation in follicular lymphoma

1 reference

12 December 2020

Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.

1 reference

12 December 2020

Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly

1 reference

12 December 2020

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting

1 reference

12 December 2020

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

1 reference

12 December 2020

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

1 reference

12 December 2020

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

1 reference

12 December 2020

Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice

1 reference

12 December 2020

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

1 reference

12 December 2020

MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma

1 reference

12 December 2020

ZINC 15--Ligand Discovery for Everyone

1 reference

12 December 2020

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor

1 reference

12 December 2020

PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas

1 reference

12 December 2020

Activity of BKM120 and BEZ235 against Lymphoma Cells.

1 reference

12 December 2020

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

1 reference

12 December 2020

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

1 reference

12 December 2020

Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma

1 reference

12 December 2020

Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma

1 reference

12 December 2020

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.

1 reference

12 December 2020

Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma

1 reference

12 December 2020

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.

1 reference

12 December 2020

A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

1 reference

12 December 2020

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

1 reference

12 December 2020

Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies

1 reference

12 December 2020

Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors

1 reference

12 December 2020

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.

1 reference

12 December 2020

Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma

1 reference

12 December 2020

Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer.

1 reference

12 December 2020

Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy

1 reference

12 December 2020

Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia

1 reference

12 December 2020

Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives

1 reference

12 December 2020

The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells

1 reference

12 December 2020

The ChEMBL database in 2017

1 reference

12 December 2020

The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).

1 reference

12 December 2020

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

1 reference

12 December 2020

mTOR Signaling in Growth, Metabolism, and Disease.

1 reference

12 December 2020

A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer

1 reference

12 December 2020

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

1 reference

12 December 2020

A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.

1 reference

12 December 2020

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.

1 reference

12 December 2020

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.

1 reference

12 December 2020

Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.

1 reference

12 December 2020

Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients

1 reference

12 December 2020

The PI3K Pathway in Human Disease

1 reference

12 December 2020

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.

1 reference

12 December 2020

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.

1 reference

12 December 2020

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

1 reference

12 December 2020

DrugBank 5.0: a major update to the DrugBank database for 2018.

1 reference

12 December 2020

PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment

1 reference

12 December 2020

Cell-Penetrating CaCO₃ Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma

1 reference

12 December 2020

Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation.

1 reference

12 December 2020

Targeting the PI3K pathway in cancer: are we making headway?

1 reference

12 December 2020

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.

1 reference

12 December 2020

Bispecific antibodies in haematological malignancies

1 reference

12 December 2020

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).

1 reference

12 December 2020

mTOR at the Transmitting and Receiving Ends in Tumor Immunity.

1 reference

12 December 2020

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

1 reference

12 December 2020

Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression.

1 reference

12 December 2020

Role of mTOR Signaling in Tumor Microenvironment: An Overview

1 reference

12 December 2020

Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers

1 reference

12 December 2020

PubChem 2019 update: improved access to chemical data

1 reference

12 December 2020

A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors

1 reference

12 December 2020

New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease

1 reference

12 December 2020

Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma

1 reference

12 December 2020

Targeting PI3K in cancer: mechanisms and advances in clinical trials

1 reference

12 December 2020

The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases

1 reference

12 December 2020

Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers

1 reference

12 December 2020

Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies

1 reference

12 December 2020

Tumor Metabolism as a Regulator of Tumor-Host Interactions in the B-Cell Lymphoma Microenvironment-Fueling Progression and Novel Brakes for Therapy

1 reference

12 December 2020

CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas

1 reference

12 December 2020

The whole-genome landscape of Burkitt lymphoma subtypes

1 reference

12 December 2020

Identifiers

DOI

10.3390/IJMS21031060

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32033478 AND SRC:MED&resulttype=core&format=json

6 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32033478 AND SRC:MED&resulttype=core&format=json

6 April 2020

PubMed publication ID

32033478

1 reference